KOKs Oppegaard

Ks Oppegaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ks Oppegaard has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • E Qvigstad

    Department of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, Oslo, Norway

    4 shared publications
  • O Istre

    Department of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, Oslo, Norway

    4 shared publications
  • B‐I Nesheim

    Department of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, Oslo, Norway

    3 shared publications
  • A Berg

    Department of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, Oslo, Norway

    2 shared publications
  • M Lieng

    Department of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, Oslo, Norway

    2 shared publications
  • B-I Nesheim

    Department of Gynaecology, Helse Finnmark, Klinikk Hammerfest, Hammerfest, Norway b Department of Obstetrics and c Department of Gynaecology, Women and Children’s Division, Ullevål University Hospital, Oslo, Norway

    1 shared publication

Latest Publications

  • Open Access

    A combination of misoprostol and estradiol for preoperative cervical ripening in postmenopausal women: a randomised controlled trial

    by Ks Oppegaard, M Lieng, A Berg, O Istre, E Qvigstad, B‐I Nesheim

    Objective  To compare the impact of 1000 μg of self‐administered vaginal misoprostol versus self‐administered vaginal placebo on preoperative cervical ripening after 2 weeks of pretreatment with estradiol vaginal tablets in postmenopausal women prior to day‐care operative hysteroscopy.Design  Randomised, double‐blind, placebo‐controlled sequential trial.Setting  Norwegian university teaching hospital.Population  Sixty‐seven postmenopausal women referred for day‐care operative hysteroscopy.Methods  The women were randomised to receive either 1000 μg of self‐administered vaginal misoprostol or self‐administered vaginal placebo on the evening before day‐care operative hysteroscopy. All women had administered a 25‐μg vaginal estradiol tablet daily for 14 days prior to the operation.Main outcome measures  Primary outcome: preoperative cervical dilatation at hysteroscopy. Secondary outcomes: difference in dilatation at recruitment and before hysteroscopy, number of women who achieved a preoperative cervical dilatation of 5 mm or more, acceptability, complications and adverse effects.Results  The mean cervical dilatation was 5.7 mm (SD, 1.6 mm) in the misoprostol group and 4.7 mm (SD, 1.5 mm) in the placebo group, the mean difference in cervical dilatation being 1.0 mm (95% CI, 0.2–1.7 mm). Self‐administered vaginal misoprostol of 1000 μg at home on the evening before day‐care hysteroscopy is safe and highly acceptable, although a small proportion of women experienced lower abdominal pain.Conclusions  One thousand micrograms of self‐administered vaginal misoprostol, 12 hours prior to day‐care hysteroscopy, after 14 days of pretreatment with vaginal estradiol, has a significant cervical ripening effect compared with placebo in postmenopausal women.


  • Open Access

    Does self‐administered vaginal misoprostol result in cervical ripening in postmenopausal women after 14 days of pre‐treatment with estradiol? Trial protocol for a randomised, placebo‐controlled sequential trial*

    by Ks Oppegaard, M Lieng, A Berg, O Istre, E Qvigstad, B‐I Nesheim

    Objective  To compare the impact of 1000 micrograms of self‐administered vaginal misoprostol versus self‐administered vaginal placebo on preoperative cervical ripening after pre‐treatment with estradiol vaginal tablets at home in postmenopausal women prior to day‐care operative hysteroscopy.Design  Randomised double‐blind placebo‐controlled sequential trial. The boundaries for the sequential trial were calculated on the primary outcomes of a difference of cervical dilatation ≥1 millimetre, with the assumption of a type 1 error of 0.05 and a power of 0.95.Setting  Norwegian university teaching hospital.Population  Postmenopausal women referred for day‐care operative hysteroscopy.Methods  The women were randomised to either 1000 micrograms of self‐administered vaginal misoprostol or self‐administered vaginal placebo the evening before day‐care operative hysteroscopy. All women had administered a 25‐microgram vaginal estradiol tablet daily for 14 days prior to the operation.Main outcome measures  Preoperative cervical dilatation (difference between misoprostol and placebo group, primary outcome), difference in dilatation before and after administration of misoprostol or placebo, number of women who achieve a preoperative cervical dilatation ≥5 millimetres, acceptability, complications and side effects (secondary outcomes).Results  Intra‐operative findings and distribution of cervical dilatation in the two treatment groups: values are given as median (range) or n (%). Difference in dilatation before and after administration of misoprostol and placebo: values are given as median (range) of intraindividual differences. Percentage of women who achieve a cervical dilatation of ≥5 mm, percentage of women who were difficult to dilate. Acceptability in the two treatment groups: values are given as completely acceptable n (%), fairly acceptable n (%), fairly unacceptable n (%), completely unacceptable n (%). Pain in the two treatment groups: pain was measured with a visual analogue scale ranging from 0 (no pain) to 10 (unbearable pain): values are given as median (range). Occurrence of side effects in the two treatment groups. Values are given as n (%). Complications given as n (%).Funding sources  No pharmaceutical company was involved in this study. A research grant from the regional research board of Northern Norway has been awarded to finance Dr K.S.O.’s leave from Hammerfest hospital as well as travel expenses between Hammerfest and Oslo, and research courses. The research grant from Prof B.I.N. (Helse Øst) funded the purchase of estradiol tablets, the manufacturing costs of misoprostol and placebo capsules from the hospital pharmacy, as well as the costs incurred for preparing the randomisation schedule and distribution of containers containing capsules to hospital. Prof B.I.N.’s research grant also funded insurance for the study participants.Conclusions  Estimated completion date 31 December 2008.


  • Comparison of self‐administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design*

    by Ks Oppegaard, B‐I Nesheim, O Istre, E Qvigstad

    Objective  To compare the impact of 1000 micrograms of self‐administered vaginal misoprostol versus self‐administered vaginal placebo at home on preoperative cervical ripening in both premenopausal and postmenopausal women before operative hysteroscopy.Design  Two separate but identical parallel, randomised, double‐blind, placebo‐controlled sequential trials, one in premenopausal women and one in postmenopausal women. The boundaries for the sequential trials were calculated on the primary outcomes of a difference of cervical dilatation ≥1 mm, with the assumption of a type 1 error of 0.05 and a power of 0.95.Setting  Norwegian university teaching hospital.Sample  Eighty‐six women referred to outpatient operative hysteroscopy.Methods  The women were randomised to either 1000 micrograms of self‐administered vaginal misoprostol or self‐administered vaginal placebo the evening before outpatient operative hysteroscopy.Main outcome measures  Preoperative cervical dilatation (primary outcome), number of women who achieve a preoperative cervical dilatation ≥5 mm, acceptability, complications and adverse effects (secondary outcomes).Results  In premenopausal women, the mean cervical dilatation was 6.4 mm (SD 2.4) in the misoprostol group and 4.8 mm (SD 2.0) in the placebo group, the mean difference in cervical dilatation being 1.6 mm (95% CI 0.5–2.7). Among the premenopausal women receiving misoprostol, 88% achieved a cervical dilatation of ≥5 mm compared with 65% in the placebo group. Twelve percent of the women who received misoprostol were difficult to dilate compared with 32% who received placebo. Dilatation was also quicker in the misoprostol group. Misoprostol had no effect on cervical ripening in postmenopausal women compared with placebo, and 43% of the women were difficult to dilate. The trials were terminated after analysis of 21 postmenopausal women and 65 premenopausal women after reaching a conclusion on the primary outcome with only 28% of the number of women needed in a fixed sample size trial. Three of 45 women who received misoprostol experienced severe lower abdominal pain, and there was an increased occurrence of light preoperative bleeding in the misoprostol group. Most women did not experience misoprostol‐related adverse effects. The majority (83% of premenopausal and 76% of postmenopausal women) found self‐administered vaginal misoprostol at home to be acceptable. There were two serious complications in the premenopausal misoprostol group: uterine perforation with subsequent peritonitis and heavy postoperative bleeding requiring blood transfusion, but these were not judged to be misoprostol related. Complications were otherwise comparatively minor and distributed equally between the two dosage groups.Conclusions  One thousand micrograms of self‐administered vaginal misoprostol 12 hours prior to operative hysteroscopy has a significant cervical ripening effect compared with placebo in premenopausal but not in postmenopausal women. Self‐administered vaginal misoprostol of 1000 micrograms at home the evening before operative hysteroscopy is safe and highly acceptable, although a small proportion of women experienced severe lower abdominal pain. There is a risk of lower abdominal pain and light preoperative bleeding with this regimen, which is very cheap and easy to use.


  • Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design*

    by Ks Oppegaard, B-I Nesheim, O Istre, E Qvigstad

    To compare the impact of 1000-microgram self-administered vaginal misoprostol versus self-administered vaginal placebo at home on preoperative cervical ripening in both premenopausal and postmenopausal women prior to outpatient resectoscopy. Randomised, double-blind, placebo-controlled sequential trial. Norwegian university teaching hospital. Premenopausal and postmenopausal women referred to outpatient resectoscopy. The women were randomised to either 1000 micrograms of self-administered vaginal misoprostol or self-administered vaginal placebo the evening before outpatient resectoscopy. Preoperative cervical dilatation, acceptability and complications. (a) Intraoperative findings and distribution of cervical dilatation in the two treatment groups. Values are given as median (range) or n (%). (b) Acceptability in the two treatment groups. Values are given as completely acceptable, n (%); fairly acceptable, n (%); fairly unacceptable, n (%) and completely unacceptable, n (%). (c) Pain in the two treatment groups. Pain was measured with a visual analogue scale score, scale ranges from 0 (no pain) to 10 (unbearable pain). Values are given as median (range). (d) Occurrence of adverse effects in the two treatment groups. Values are given as n (%). (e) Complications, given as n (%).